Submitted for Publication: March 24, 2011; final revision received September 30, 2011; accepted October 10, 2011.
Author Contributions: Dr Kessler takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors had full access to all the data in the study.
Financial Disclosure: Dr Kessler has been a consultant for AstraZeneca; Analysis Group; Bristol-Myers Squibb; Cerner-Galt Associates; Eli Lilly and Company; GlaxoSmithKline, Inc; HealthCore, Inc; Health Dialog; Integrated Benefits Institute; John Snow, Inc; Kaiser Permanente; Matria, Inc; Mensante; Merck & Co, Inc; Ortho-McNeil Janssen Scientific Affairs; Pfizer, Inc; Primary Care Network; Research Triangle Institute; sanofi-aventis; Shire US, Inc; SRA International, Inc; Takeda Global Research & Development; Transcept Pharmaceuticals, Inc; and Wyeth-Ayerst; has served on advisory boards for Appliance Computing II; Eli Lilly & Company; Mindsite; Ortho-McNeil Janssen Scientific Affairs; and Wyeth-Ayerst; and has had research support for his epidemiologic studies from Analysis Group, Inc; Bristol-Myers Squibb; Eli Lilly and Company; EPI-Q; GlaxoSmithKline, Inc; Johnson & Johnson Pharmaceuticals; Ortho-McNeil Janssen Scientific Affairs; Pfizer, Inc; sanofi-aventis; and Shire US, Inc.
Funding/Support: The NCS-A is supported by grants U01-MH60220, R01-MH66627, and U01MH060220-09S1 from the National Institute of Mental Health with supplemental support from the National Institute on Drug Abuse, the Substance Abuse and Mental Health Services Administration, the Robert Wood Johnson Foundation (grant 044780), and the John W. Alden Trust. The work of Dr Merikangas is supported by the National Institute of Mental Health Intramural Research Program. The work of Dr Zaslavsky is supported by grant R01-MH66627 from the National Institute of Mental Health. The World Mental Health Data Coordination Centers have received grants R01-MH070884, R13-MH066849, R01-MH069864, and R01-MH077883 from the National Institute of Mental Health; R01-DA016558 from the National Institute on Drug Abuse; and FIRCA R03-TW006481 from the Fogarty International Center of the National Institutes of Health; and support from the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, and the Pan American Health Organization. The World Mental Health Data Coordination Centers have also received unrestricted educational grants from AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline, Inc; Ortho-McNeil; Pfizer, Inc; sanofi-aventis; and Wyeth.
Role of the Sponsors: The sponsors had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; and the preparation, review, or approval of the manuscript.
Disclaimer: The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of any of the sponsoring organizations, agencies, or US Government.
Additional Information: A complete list of NCS-A publications can be found at http://www.hcp.med.harvard.edu/ncs. A public use version of the NCS-A data set is available for secondary analysis. Instructions for accessing the dataset can be found at http://www.hcp.med.harvard.edu/ncs/index.php. The NCS-A is performed in conjunction with the World Health Organization World Mental Health Survey Initiative. A complete list of World Mental Health publications can be found at http://www.hcp.med.harvard.edu/wmh/.
Additional Contributions: We thank the staff of the World Mental Health Data Collection and Data Analysis Coordination Centers for assistance with instrumentation, fieldwork, and consultation on data analysis.